Economic value: £152m
Rights to receive royalties from obesity drug programmes
- HealthTech
- Top 10 holdings
*Holding percentages in portfolio companies reflect the undiluted beneficial equity interest excluding debt, unless otherwise explicitly stated.
Showing XX of 56
Economic value: £152m
Rights to receive royalties from obesity drug programmes
- HealthTech
- Top 10 holdings